Um estudo de JNJ-68284528, uma terapia quimérica de células T receptoras de antígenos (CAR-T) direcionada contra o antígeno de maturação de células B (BCMA) em participantes com mieloma múltiplo (CARTITUDE-2)
Um estudo aberto de fase 2, multicoorte de JNJ-68284528, uma terapia quimérica de células T receptoras de antígenos (CAR-T) direcionada contra BCMA em indivíduos com mieloma múltiplo
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Acesso expandido
Contactos e Locais
Locais de estudo
-
-
-
Hamburg, Alemanha, 20246
- Universitaetsklinikum Hamburg Eppendorf
-
Würzburg, Alemanha, 97080
- Universitatsklinikum Wurzburg
-
-
-
-
-
Riyadh, Arábia Saudita, 11211
- King Faisal Specialist Hospital & Research Center
-
-
-
-
-
Ghent, Bélgica, 9000
- UZ Gent
-
Leuven, Bélgica, 3000
- UZ Leuven
-
-
-
-
-
Pamplona, Espanha, 31008
- Clinica Univ. de Navarra
-
Salamanca, Espanha, 37007
- Hosp Clinico Univ de Salamanca
-
-
-
-
California
-
San Diego, California, Estados Unidos, 92037
- University Of California San Diego
-
San Francisco, California, Estados Unidos, 94143
- University of California San Francisco
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510
- Yale University School Of Medicine
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Westwood, Kansas, Estados Unidos, 66205
- University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40207
- Norton Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Dana Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic Rochester
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63108
- Washington University School Of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Hackensack University Medical Center
-
New Brunswick, New Jersey, Estados Unidos, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Roswell Park Cancer Institute
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan-Kettering Cancer Center
-
New York, New York, Estados Unidos, 10029
- Mount Sinai Medical Center
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204
- Levine Cancer Institute, Carolinas HealthCare System
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health And Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Thomas Jefferson University
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- University of Pittsburgh
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- University of Texas Southwestern Medical Center
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- University of Utah
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- University of Virginia
-
Richmond, Virginia, Estados Unidos, 23298
- Virginia Commonwealth University - Massey Cancer Center
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53705
- University of Wisconsin Carbone Cancer Center
-
-
-
-
-
Lille, França, 59037
- CHRU de Lille Hopital Claude Huriez
-
Nantes, França, 44093
- C.H.U. Hotel Dieu - France
-
Paris, França, 75475
- Hopital Saint Louis
-
-
-
-
-
Amsterdam, Holanda, 1081 HV
- VU Medisch Centrum
-
Groningen, Holanda, 9713 GZ
- University Medical Center Groningen
-
-
-
-
-
Ramat Gan, Israel, 52621
- Sheba Medical Center Tel Hashomer
-
Tel Aviv, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Cohort A: Received a minimum of 1 to a maximum of 3 prior lines of therapy including a proteasome inhibitor (PI) and immunomodulatory therapy (IMiD), and lenalidomide refractory per International Myeloma Working Group (IMWG) guidelines
- Cohort B: Received one line of prior therapy including a PI and an IMiD, and disease progression per IMWG criteria less than or equal to (<=) 12 months after treatment with autologous stem cell transplantation (ASCT) or <=12 months from the start of anti-myeloma therapy for participants who have not had an ASCT
- Cohort C: Previously treated with a PI, an IMiD, an anti-CD38 monoclonal antibody and B-cell maturation antigen (BCMA)-directed therapy
- Cohort D: Newly diagnosed multiple myeloma per IMWG with a history of 4 to 8 total cycles of initial therapy, including induction, high-dose therapy, and ASCT with or without consolidation
- Cohort E: Have newly diagnosed multiple myeloma without prior therapy (one cycle of prior therapy before enrollment is acceptable) and classified as high risk defined as either: 1) International Staging System (ISS) stage III criteria, Beta 2 microglobulin greater than or equal to (>=) 5.5 milligrams per liter (mg/L) (via local or central laboratory assessment) or 2) high risk cytogenetic features del(17/17p), t (14;16), t(14;20), 1q amplification (at least 4 total copies) in at least 20 percent (%) of the total plasma cell population
- Cohort F:
- Participant must have a documented efficacy response of very good partial response (VGPR) or better, without progressive disease prior to enrollment, as assessed per IMWG 2016 criteria
- Received initial therapy as specified below. The dose/schedule of cycles administered will be as per standard of care. It is acceptable for up to 1 cycle of the protocol-specified regimens to be missing one of the listed agents (example, held due to toxicity). Acceptable combinations include: At least 5 to 8 cycles of initial therapy with daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd). The dose/schedule of cycles administered will be as per standard of care or; at least 4 to 8 cycles of initial therapy with daratumumab, lenalidomide and dexamethasone (D-Rd) or; at least 4 to 8 cycles of initial therapy with a carfilzomib-based triplet or quadruplet regimen
- For US sites only: Cohort G: Not considered for high-dose chemotherapy with autologous stem cell transplantation (ASCT) due to: a) Ineligibility due to advanced age; or b) Ineligibility due to presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT; or c) Subject refusal of high-dose chemotherapy with ASCT as initial treatment
- Cohorts A, B, C, E and Cohort G (for US sites only):
- Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL) or urine M-protein level >=200 milligrams (mg)/24 hours
- Light chain multiple myeloma in whom only measurable disease is by serum free light chain (FLC) levels in the serum: Serum immunoglobulin FLC >=10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio
- Cohort A: For participants with neither serum nor urine measurable disease, baseline positron emission tomography/ computed tomography (PET/CT) or whole -body magnetic resonance imaging (MRI) may be used to satisfy the measurable disease criteria. A minimum of one lesion with a bi-dimensional measurement of at least 1 centimeter (cm)*1 cm is required
- Cohorts B, C: For participants with neither serum nor urine measurable disease, baseline positron emission tomography/ computed tomography (PET/CT) or whole body magnetic resonance imaging (MRI) may be used to satisfy the measurable disease criteria
- Cohorts A, B, C, D, E, F and Cohort G (for US sites only): Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
Exclusion Criteria:
- Cohorts A, B, D, F: Any therapy that is targeted to BCMA
- Cohorts A, B, C, D, F: Prior treatment with chimeric antigen receptor T (CAR-T) therapy directed at any target
- Cohorts A, B, C, D, F:
- Ongoing toxicity from previous anticancer therapy must resolve to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy
- Received a cumulative dose of corticosteroids equivalent to >=70 mg of prednisone within the 7 days (Cohort A, B, C, F) or 14 days (Cohort D) prior to apheresis
- Serious underlying medical condition, such as (a) evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection; (b) active autoimmune disease or a history of autoimmune disease within 3 years; (c) overt clinical evidence of dementia or altered mental status; (d) any history of Parkinson's disease or other neurodegenerative disorder
- Cohorts A, B, C, D, E, F: Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma
- Cohort F and Cohort G (for US sites only): Active malignancies (that is, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. The only allowed exceptions are: a) non-muscle invasive bladder cancer treated within the last 24 months that is considered completely cured; b) skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured; c) non-invasive cervical cancer treated within the last 24 months that is considered completely cured; d) localized prostate cancer (N0M0): with a Gleason score of greater than or equal to (=>)6, treated within the last 24 months or untreated and under surveillance, with a Gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence, or history of localized prostate cancer and receiving androgen deprivation therapy and considered to have a very low risk of recurrence, e) breast cancer: adequately treated lobular carcinoma in situ or ductal carcinoma in situ, or history of localized breast cancer and receiving antihormonal agents and considered to have a very low risk of recurrence; f) malignancy that is considered cured with minimal risk of recurrence
- Cohort E and Cohort G (for US sites only): Frailty index of >= 2 according to Myeloma Geriatric Assessment score
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: JNJ-68284528
Single group assignment-Post lymphodepletion, JNJ-68284528 single infusion given to Part A participants: Cohort A (Progressive disease post 1-3 prior lines of therapy), Cohort B (Early relapse post front-line), Cohort C(Relapsed/refractory multiple myeloma post PI, IMiD,anti-CD38,anti-BCMA therapy), Cohort D(Less than CR post ASCT front-line therapy, some participants will receive JNJ-68284528 then lenalidomide), Cohort F(Newly diagnosed multiple myeloma [NDMM], standard risk [International Staging System Stage I/II] and post initial therapy); Cohort E(NDMM,transplant not planned, high risk disease) will first receive quadruplet induction regimen of daratumumab, bortezomib, lenalidomide and dexamethasone(D-VRd) then lymphodepletion and JNJ-68284528 then consolidation regimen of lenalidomide. Enrollment is closed for Cohorts A,B,C,D,E and F. For US sites only: Part B:Cohort G (NDMM, transplant not planned) will receive daratumumab, lenalidomide and dexamethasone followed by cilta-cel. |
Participants in Cohorts A,B,C, D, E, F and Cohort G (for US sites only) will receive JNJ-68284528 intravenously.
Outros nomes:
Some participants in Cohort D and all participants in Cohorts E and Cohort G (for US sites only) will also receive lenalidomide capsules orally. Participants in Cohorts E and Cohort G (for US sites only) will also receive daratumumab subcutaneous (SC) injection. Participants in Cohorts E will also receive bortezomib subcutaneously. Participants in Cohorts E and Cohort G (for US sites only) will also receive dexamethasone orally or intravenously. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cohorts A, B, C, D, E, and F: Percentage of Participants with Negative Minimal Residual Disease (MRD)
Prazo: At least 1 year after JNJ-68284528 infusion on Day 1
|
MRD negative rate is the percentage of participants who achieve MRD negative status by evaluation of bone marrow aspirate as defined by the International Myeloma Working Group (IMWG) criteria. |
At least 1 year after JNJ-68284528 infusion on Day 1
|
|
For US sites only: Cohort G: Percentage of Participants with Sustained MRD Negative Complete Response (CR)
Prazo: At least 1 year after JNJ-68284528 infusion on Day 1
|
Sustained MRD-negative CR is defined as participants with CR or better who sustain MRD-negative status, as determined by next-generation sequencing (NGS) or next generation flowcytometry (NGF) with sensitivity of 10^-5, for at least 12 months without any examination showing MRD positive status or progressive disease in between. |
At least 1 year after JNJ-68284528 infusion on Day 1
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall Response Rate (ORR)
Prazo: Up to 8 years and 10 months
|
ORR is defined as the percentage of participants who achieve a partial response (PR) or better according to the IMWG criteria. |
Up to 8 years and 10 months
|
|
Cohorts A, B, C, D, E, and F: VGPR or Better Rate
Prazo: Up to 8 years and 10 months
|
The VGPR or better rate (stringent complete responses [sCR] + complete response [CR] + VGPR), defined as the percentage of participants achieving VGPR or better response according to IMWG criteria during or after the study treatment. |
Up to 8 years and 10 months
|
|
Cohorts A, B, C, D, E, and F: Clinical Benefit Rate (CBR)
Prazo: Up to 8 years and 10 months
|
CBR is defined as the percentage of participants who achieve ORR (sCR + CR + VGPR + PR) + minimal response (MR) according to the IMWG criteria. |
Up to 8 years and 10 months
|
|
Duration of Response (DOR)
Prazo: Up to 8 years and 10 months
|
DOR will be calculated among responders from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG criteria. |
Up to 8 years and 10 months
|
|
Time to Response (TTR)
Prazo: Up to 8 years and 10 months
|
TTR is defined as the time from the date of the initial infusion of JNJ-68284528 and the first efficacy evaluation that the participant has met all criteria for PR or better. |
Up to 8 years and 10 months
|
|
Cohorts A, B, C, D, E, and F: MRD Negative Rate at 12 Months for Participants who Achieve a Complete Response (CR)
Prazo: 12 months
|
MRD negative rate at 12 months for participants who achieved a complete response (CR) is defined as the percentage of participants who are MRD negative by bone marrow aspirate and meet the IMWG criteria for CR at 12 months after initial dose of JNJ-68284528 and before disease progression or starting subsequent therapy including retreatment of JNJ-68284528. |
12 months
|
|
Time to MRD Negativity
Prazo: Up to 8 years and 10 months
|
Time to MRD negativity will be calculated in participants who are MRD negative by bone marrow aspirate from the date of the initial infusion of JNJ-68284528 to the initial date of reaching the MRD negative status. |
Up to 8 years and 10 months
|
|
Duration of MRD Negativity
Prazo: Up to 8 years and 10 months
|
Duration of MRD negativity will be calculated among participants who are MRD negative by bone marrow aspirate from the date of initial MRD negativity to the date when MRD is detected at the same threshold (10^-5). |
Up to 8 years and 10 months
|
|
Cohorts A, B, C, D, E, and F: MRD Negative Rate Across Clinical Response
Prazo: Up to 8 years and 10 months
|
MRD negative rate across clinical response groups will be assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR) or very good partial response (VGPR) according to the IMWG criteria during or after the study treatment. MRD negative rate is defined as the percentage of participants who have negative MRD by bone marrow aspirate at any timepoint. |
Up to 8 years and 10 months
|
|
Number of Participants with Adverse Events by Severity
Prazo: Up to 8 years and 10 months
|
An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), with the exception of cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS and ICANS will be evaluated according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading. |
Up to 8 years and 10 months
|
|
Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability
Prazo: Up to 8 years and 10 months
|
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. |
Up to 8 years and 10 months
|
|
Number of Participants with Laboratory Abnormalities
Prazo: Up to 8 years and 10 months
|
Number of participants with laboratory abnormalities will be reported. |
Up to 8 years and 10 months
|
|
Number of Participants with Vital Signs Abnormalities
Prazo: Up to 8 years and 10 months
|
Number of participants with vital signs abnormalities will be reported. |
Up to 8 years and 10 months
|
|
Cohorts A, B, C, D, E, and F: Levels of B-Cell Maturation Antigen (BCMA) Expressing Cells and Soluble BCMA
Prazo: Up to 1 year
|
Levels of expression of BCMA-expressing plasma cells in the bone marrow as well as the level of soluble BCMA in blood will be reported. |
Up to 1 year
|
|
Cohorts A, B, C, D, E, and F: Systemic Inflammatory Cytokine Concentrations
Prazo: Up to 1 year
|
Blood cytokine concentrations (Interleukin [IL]-6, IL-15, IL-10, and Interferon [IFN-gamma]) will be measured for biomarker assessment. |
Up to 1 year
|
|
Cohorts A, B, C, D, E, and F: Levels of JNJ-68284528 T Cell Expansion (proliferation), and Persistence
Prazo: Up to 1 year
|
Levels of JNJ-68284528 T cell expansion (proliferation), and persistence via monitoring CAR-T positive cell counts and CAR transgene level will be reported. |
Up to 1 year
|
|
Cohorts A, B, C, D, E, and F: Number of Participants with Anti-JNJ-68284528 Antibodies
Prazo: Up to 1 year
|
Number of participants exhibiting anti-drug antibodies for JNJ-68284528 will be reported. |
Up to 1 year
|
|
For US sites only: Cohort G: Percentage of Participants with Complete Response (CR) or Better
Prazo: Up to 8 years and 10 months
|
CR or better is defined as the percentage of participants achieving CR or sCR prior to subsequent antimyeloma therapy in accordance with the IMWG criteria during or after the study treatment. |
Up to 8 years and 10 months
|
|
For US sites only: Cohort G: Percentage of Participants with MRD-negative CR or sCR
Prazo: Up to 8 years and 10 months
|
MRD-negative CR/sCR is defined as the percentage of participants who achieve MRD-negative status, as determined by NGS/NGF with sensitivity of 10^-5, at any time after enrollment and prior to progressive disease or subsequent antimyeloma therapy and who achieve CR/sCR or better. |
Up to 8 years and 10 months
|
|
For US sites only: Cohort G: Progression-free Survival on Next-line Therapy (PFS2)
Prazo: Up to 8 years and 10 months
|
PFS2 is defined as the time interval between the start of study treatment and date of event, which is defined as death from any cause or PD as assessed by investigator that starts after the next line of therapy, whichever occurs first. |
Up to 8 years and 10 months
|
|
For US sites only: Cohort G: Overall Survival (OS)
Prazo: Up to 8 years and 10 months
|
OS is defined as the time from the start of study treatment to the date of the participant's death. |
Up to 8 years and 10 months
|
|
For US sites only: Cohort G: Progression-free Survival (PFS)
Prazo: Up to 8 years and 10 months
|
PFS is defined as the time from the start of study treatment to the date of first documented disease progression, as defined in the IMWG criteria, or death due to any cause, whichever occurs first. |
Up to 8 years and 10 months
|
|
For US sites only: Cohort G: Number of Participants with Measurable Replication Competent Lentivirus (RCL) in Whole Blood
Prazo: Up to 8 years and 10 months
|
Number of participants with measurable RCL in whole blood will be reported. |
Up to 8 years and 10 months
|
|
For US sites only: Cohort G: Time to Subsequent Anti-Myeloma Therapy
Prazo: Up to 8 years and 10 months
|
Time to subsequent anti-myeloma treatment is defined as the time from start of study treatment to the start of subsequent anti-myeloma treatment. |
Up to 8 years and 10 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Vasculares
- Doenças cardiovasculares
- Neoplasias
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Neoplasias de Células Plasmáticas
- Distúrbios hemostáticos
- Paraproteinemias
- Distúrbios das Proteínas Sanguíneas
- Distúrbios hemorrágicos
- Doenças hemic e linfáticas
- Mieloma múltiplo
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Ácidos carboxílicos
- Compostos policíclicos
- Piperidinas
- Produtos químicos inorgânicos
- Pregada
- Pregnas
- Esteróides
- Compostos de anel fundido
- Esteróides, fluorados
- Pregadienetriols
- Ácidos borônicos
- Ácidos, não carboxílico
- Ácidos
- Compostos de boro
- Pirazinas
- Ftalimidas
- Ácidos ftaléticos
- Ácidos, carbocíclicos
- Piperidones
- Isoindoles
- Lenalidomida
- Bortezomibe
- Dexametasona
- daratumumab
Outros números de identificação do estudo
- CR108581
- 2018 (Concessão/Contrato do NIH dos EUA)
- 2018-004124-10 (Número EudraCT)
- 68284528MMY2003 (Outro identificador: Janssen Research & Development, LLC)
- 2023-506587-13-00 (Identificador de registro: EUCT number)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .